BAC appoints Dr Andrew Carr as Chairman of Supervisory Board
BAC BV, the Bio Affinity Company, announced the appointment of Dr Andrew Carr as Chairman to its Supervisory Board.
Dr Carr brings a wealth of experience in the biotech industry to the role. As CEO of Amersham Biosciences and a Director of Amersham plc, Dr Carr played a key role in growing the Life Science Research and Bio-separations business units until the successful acquisition of Amersham by GE Healthcare in 2004. Dr Carr is currently a Non-executive Director and Chairman of several European private equity funded companies and has been involved in raising finance and execution of third party deals.
Dr Carr is currently Chairman of deltaDOT Ltd and Teraview Ltd, a Director of SciBridge Ltd, and an advisor to SpinX-Technologies SA. He is also a member of the Imperial Innovations investment advisory group. Dr Carr has a PhD in Zoology from the University of Nottingham.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.